[GNI Group] Completion of U.S.-China Subsidiary Acquisition｜May 2026

Performance Overview

This document reports on the completion of GNI Group’s full acquisition of Gyre Therapeutics. The acquisition was executed via a share exchange totaling approximately 300 million USD, transforming Gyre into a fully integrated biopharmaceutical company based in the U.S. and China. Post-acquisition, Gyre holds commercial assets and a pipeline spanning multiple therapeutic areas, with a particular focus on accelerating the development of treatments for fibrosis and inflammatory diseases.

Future Outlook and Impact on Shareholders

Through integration, Gyre’s management aims to leverage its U.S. and Chinese operations for global growth. Notably, the company anticipates the submission of a new drug application for the pulmonary fibrosis treatment F351 in China, and progress in clinical trials for pneumoconiosis and radiation-induced lung injury is expected. These developments are projected to enhance long-term corporate value and benefit shareholders.